Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Chapuis

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Oncotarget|February 4, 2016
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cellsJennifer Varin, Laury Poulain, Mikael Hivelin, et al.
Blood Cancer Journal|November 16, 2018
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosisSihem Tarfi, Véronique Harrivel, Florent Dumezy, et al.
Annals of Intensive Care|July 17, 2016
Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore studyBertrand Sauneuf, Claire Bouffard, Edouard Cornet, et al.
Pharmacological Research|July 6, 2016
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patientsAlicja Puszkiel, Mélanie White-Koning, Nicolas Dupin, et al.
Journal of Clinical Medicine|October 14, 2022
Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 PatientsCamille Chenevier-Gobeaux, Morgane Ducastel, Jean-François Meritet, et al.
Oncotarget|February 25, 2016
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesisAnna Raimbault, Cecile Pierre-Eugene, Alexandra Rouquette, et al.
Cytometry. Part B, Clinical Cytometry|April 10, 2019
The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromesAnna Raimbault, Raphael Itzykson, Lise Willems, et al.
Blood|May 22, 2009
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemiaJerome Tamburini, Alexa S Green, Valerie Bardet, et al.
Oncogenesis|October 23, 2020
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemiaGodelieve Meunier, Rudy Birsen, Clarisse Cazelles, et al.
Cytometry. Part B, Clinical Cytometry|September 10, 2019
Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDSSylvain Barreau, Alexa S Green, Charles Dussiau, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Oncotarget|February 4, 2016
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cellsJennifer Varin, Laury Poulain, Mikael Hivelin, et al.
Blood Cancer Journal|November 16, 2018
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosisSihem Tarfi, Véronique Harrivel, Florent Dumezy, et al.
Annals of Intensive Care|July 17, 2016
Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore studyBertrand Sauneuf, Claire Bouffard, Edouard Cornet, et al.
Pharmacological Research|July 6, 2016
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patientsAlicja Puszkiel, Mélanie White-Koning, Nicolas Dupin, et al.
Journal of Clinical Medicine|October 14, 2022
Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 PatientsCamille Chenevier-Gobeaux, Morgane Ducastel, Jean-François Meritet, et al.
Oncotarget|February 25, 2016
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesisAnna Raimbault, Cecile Pierre-Eugene, Alexandra Rouquette, et al.
Cytometry. Part B, Clinical Cytometry|April 10, 2019
The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromesAnna Raimbault, Raphael Itzykson, Lise Willems, et al.
Blood|May 22, 2009
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemiaJerome Tamburini, Alexa S Green, Valerie Bardet, et al.
Oncogenesis|October 23, 2020
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemiaGodelieve Meunier, Rudy Birsen, Clarisse Cazelles, et al.
Cytometry. Part B, Clinical Cytometry|September 10, 2019
Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDSSylvain Barreau, Alexa S Green, Charles Dussiau, et al.
Pageof 10